

### **Amendments to the Claims:**

The following amendments replace all prior claims and amendments in this case.

1-40. (canceled)

41. (currently amended) A method of diagnosing ~~an immune-related~~ a memory T cell mediated disease in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide SEQ ID NO:2386, (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of ~~an immune-related~~ a memory T cell mediated disease in the mammal from which the test tissue cells were obtained.

42. (currently amended) A method of diagnosing ~~an immune-related~~ a memory T cell mediated disease in a mammal, said method comprising (a) contacting a PRO polypeptide of SEQ ID NO:2386 anti-PRO antibody with a test sample of tissue cells obtained from said mammal and (b) detecting the formation of a complex between the antibody and the polypeptide in the test sample, wherein formation of said complex is indicative of the presence of ~~an immune related~~ a memory T cell mediated disease in the mammal from which the test tissue cells were obtained.

43. (currently amended) A method of diagnosing ~~an inflammatory~~ a memory T cell mediated immune response in a mammal, said method comprising detecting the level of expression of a gene encoding a PRO polypeptide of SEQ ID NO:2386 (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher or lower level of expression of said gene in the test sample as compared to the control sample is indicative of the presence of ~~an inflammatory a~~ memory T cell mediated immune response in the mammal from which the test tissue cells were obtained.

44. (previously presented) The method of claim 41 or 43 wherein the gene expression levels are determined by hybridization of nucleic acid obtained from the test and normal biological samples to one or more probes specific for the nucleic acid encoding the polypeptide of SEQ ID NO:2386.

45. (currently amended) The method of claim 44 wherein hybridization is performed under stringent conditions, wherein said stringent conditions use 50% formamide, ~~5x times~~ SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, ~~5x times~~ Denhardt's solution, sonicated salmon sperm DNA (50 ~~[[.mu.]]~~  $\mu$ g/ml), 0.1% SDS, and 10% dextran sulfate at ~~42.degree.~~ °C.

46. (cancelled)

47. (currently amended) The method of claim 45 wherein the nucleic acids obtained from the test and normal biological samples are ~~[[cDNAs]]~~ mRNAs.

48. (currently amended) The method of claim 47 wherein the nucleic acids obtained from the test and normal biological samples are reverse transcribed and labeled to generate cDNA probes which are then hybridized ~~placed~~ on microarrays.

49. (previously presented) The method of claim 42 wherein said antibody is a monoclonal antibody.

50. (previously presented) The method of claim 49 wherein said antibody is a humanized antibody.

51. (previously presented) The method of claim 49 wherein said antibody is an antibody fragment.

52. (previously presented) The method of claim 49 wherein said antibody is labeled.